论文部分内容阅读
[目的]探讨疏肝健脾法防治中晚期肝癌介入治疗后肝储备功能的损害。[方法]69例中晚期原发性肝癌患者随机分为观察组(n=35)及对照组(n=34)。2组患者介入治疗后均予西药常规护肝治疗及对症处理,观察组在介入治疗前7天开始服用疏肝健脾中药,介入治疗后随症加减。2组在第1、2次介入前和第2次介入后4周分别检查吲哚靛青绿15min潴留率(ICGR15)。[结果]第1次介入前ICGR15:观察组为(11.23±7.26)%,对照组(11.83±7.16)%;第2次介入前ICGR15:观察组(11.62±5.01)%,对照组(14.88±9.36)%,P<0.05;第2次介入后1个月ICGR15:观察组(12.08±6.30)%,对照组(18.20±10.15)%,P<0.05。[结论]疏肝健脾法可防治肝癌介入后所引起的肝储备功能损害。
[Objective] To explore the effect of Shuganjianpi method on prevention and treatment of liver reserve after interventional treatment of advanced liver cancer. [Method] Ninety-nine patients with advanced primary liver cancer were randomly divided into observation group (n = 35) and control group (n = 34). The patients in both groups received routine liver protection and symptomatic treatment after interventional therapy. The observation group began to take Shuganjianpi Chinese medicine 7 days before interventional treatment, and were followed up after treatment. The retention of indole indocyanine green 15 minutes (ICGR15) was examined before the first and second interventions and four weeks after the second intervention. [Results] Before the first intervention, ICGR15 was (11.23 ± 7.26)% in the observation group and (11.83 ± 7.16)% in the control group, 11.62 ± 5.01% in the second intervention group and 14.88 ± 9.36)%, P <0.05; ICGR15: 12.08 ± 6.30% in the observation group and 18.20 ± 10.15% in the control group at 1 month after the second intervention, P <0.05. [Conclusion] Shuganjianpi method can prevent the impairment of hepatic reserve after liver cancer intervention.